Our Science
There is great unmet medical need for revolutionary approaches to fine-tune immune responses for the treatment of autoimmune diseases.
Achieving potent immune modulation requires the active engagement of immunomodulatory pathways, including transcription factors and metabolic pathways. At Immunocodex, we have developed a cutting-edge platform using novel mRNA vaccines which are capable of inducing antigen-specific immunomodulation for the safe and effective treatment of autoimmune diseases.
Our therapies are designed to specifically target Dendritic cells – powerful immune cells which control the balance between pro-inflammatory and anti-inflammatory responses.
Kenison et al, Nat. Rev. in Immunology 2023
Our Approach
Our approach relies on Lipid Nanoparticle (LNP) delivery of mRNA which simultaneously encodes two key signals:
1. Active tolerance-inducing molecule 2. Disease-specific autoantigen
Co-delivery of these two signals ensures a strong therapeutic signal which suppresses disease-specific immune responses, while limiting off-target systemic side effects.
Lead Programs:
Our lead programs target the development of clinically safe and effective novel therapies for the treatment of Type 1 Diabetes, Multiple Sclerosis and Celiac Disease.
Our therapies have shown pre-clinical success in inducing antigen-specific immunosuppression and reducing disease symptoms and pathology. We are rapidly advancing our targeted therapeutics towards clinical testing.
